)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Orchestra BioMed Holdings (OBIO) investor relations material
Orchestra BioMed Holdings Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary12 Aug, 2025
Executive summary
Net loss for the six months ended June 30, 2025 was $38.1 million, up 29% year-over-year, with an accumulated deficit of $348.0 million as of June 30, 2025.
Secured over $111 million in proceeds and committed capital through strategic transactions and equity offerings, with major contributions from Medtronic and Ligand.
Achieved key FDA milestones: Breakthrough Device Designation for AVIM therapy, expanded BACKBEAT study enrollment, and IDE approval for Virtue SAB pivotal trial.
Expanded strategic collaboration with Medtronic for future AVIM therapy-enabled leadless pacemakers.
Intellectual property portfolio for AVIM therapy grew to 137 issued patents worldwide.
Financial highlights
Total revenue for the six months ended June 30, 2025 was $1.7 million, up 22% year-over-year.
Cash and marketable securities totaled $33.9 million at June 30, 2025, estimated at $101 million as of August 12, 2025, including recent financings.
Net cash used in operating activities was $32.1 million for the six months ended June 30, 2025.
Research and development expenses increased 35% to $27.3 million for the six months ended June 30, 2025.
Net loss was $19.4 million ($0.50 per share) in Q2 2025, compared to $16.0 million ($0.45 per share) in Q2 2024.
Outlook and guidance
Cash runway, including recent financings and committed future proceeds, is expected to fund operations into the second half of 2027.
Increased spending planned for pivotal clinical trials of AVIM therapy and Virtue SAB, with enrollment and regulatory milestones anticipated in 2025-2026.
BACKBEAT study enrollment completion targeted for mid-2026; Virtue Trial initiation planned for the second half of 2025.
When is BACKBEAT study enrollment completion expected?
Discuss the implications of AVIM's Breakthrough Device Designation.
Explain the purpose of the Virtue Trial.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Orchestra BioMed Holdings earnings date
Q3 202512 Nov, 2025
Next Orchestra BioMed Holdings earnings date
Q3 202512 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on accelerating the development and commercialization of high-impact medical technologies. The company operates through a partnership-enabled business model, collaborating with leading medical device companies to bring its innovations to market. Its key product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT), which is designed to treat hypertension in patients with pacemakers, and Virtue Sirolimus AngioInfusion Balloon (SAB), intended for the treatment of atherosclerotic artery disease. Orchestra BioMed has strategic partnerships with companies like Medtronic and Terumo Corporation to advance the development and global commercialization of these products. The company is headquartered in New Hope, Pennsylvania, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage